Crossing the SynBio Valley of Death with Proven Solutions
Most synbio companies die between "works in the lab" and "works at scale." Freedom-to-operate issues, process robustness, CMC readiness. The valley of death is real and it swallows good science. @IngenzaLtd has been helping teams cross it for 20 years. Leonardo Magneschi is bringing case studies from the front lines to SynBioBeta 2026: what fails most often, what fixes it fastest, and how to design for manufacturability from day one. Their inGenius® platform has a 100% success rate producing customer targets across 12 different biomanufacturing hosts. @SynBioBeta 2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK
DeepSeqAI Trains on Function to Future‑proof Biologics
Most AI protein tools are trained on structure. DeepSeqAI trains on function. They're running billions of experimental protein-protein interactions through their platform to map biologics against viruses, immune receptors, and the entire human proteome. The goal: candidates that hold up against...
One Gene Therapy Platform Could Cure Obesity and More
Eric Kelsic makes the compelling case on using gene therapy technology to eventually treat common diseases, like obesity: “Fundamentally, we all share the same genetics." Because our bodies run on the same genetic blueprint, a disease - whether common or rare -...
A Decade of DNA Innovation Powers AI‑Biology Convergence
Ten years ago, Emily Leproust had an idea to rewrite how DNA gets made. Most people thought it wouldn't work. Today, Twist Bioscience is the infrastructure layer for biotech and pharma worldwide. At SynBioBeta 2026, she's on the main stage with John...
Memory, Not Models, Limits AI-Driven Scientific Discovery
The biggest bottleneck for agentic AI in science isn't the model. It's memory. What was tried. What failed. Why decisions were made. That institutional knowledge lives in scattered notebooks, emails, and people's heads — and most AI tools have no access to...
P&G Brings Biotech Ingredients to Mass‑market Consumer Products
P&G doesn't move on new ingredients unless the science is bulletproof and the consumer performance is there. They're moving on biotech. Three R&D leaders from Procter & Gamble are at SynBioBeta 2026 to talk about how bio-derived ingredients are making it into...
AI‑Designed Enzymes Break Evolution’s Limits for Biomanufacturing
Nature never designed enzymes for industrial manufacturing. It designed them to survive. That mismatch is one of the biggest bottlenecks in biomanufacturing — and most of the industry has been working around it with incremental fixes for decades. Matthew Thompson from Biomatter...
Cell‑free DNA Manufacturing Eliminates Cloning Bottlenecks
Your DNA synthesis workflow is probably slowing you down more than you think. Cloning introduces delays, contamination risk, and hard limits on what you can build. Most of the field is still living with these constraints — even as mRNA therapeutics,...
Self‑immunized Man’s Blood Yields Universal Antivenom
A truck mechanic from Wisconsin spent 18 years injecting himself with venom from the world's deadliest snakes. 700 doses. 200+ bites. He taught himself immunology from a textbook. His name is Tim Friede. His blood may end up saving hundreds of...
NMN Daily Restores NAD, Supports Healthy Aging
David Sinclair takes 1 gram of NMN every single day. Here's why. As you age, your body loses up to 50% of a molecule called NAD. NAD is a molecule that acts like fuel powering your sirtuin genes - the genes responsible...
40 AI‑Biology Leaders Converge at SynBioBeta 2026
40 of the biggest names in AI x Biology will be on stage at @SynBioBeta May 4–7 in San Jose, California. Get your tickets here: https://t.co/8abYWJ1GbK Marc Tessier-Lavigne (@Xaira_Thera), Kim Branson (@GSK ). @GabriCorso (Boltz). Peter Clark (@novonordisk ). Dave Hallett (@RecursionPharma). Ashoka...
Interpretability Becomes New Scalability in Synthetic Biology
One of the most clarifying conversations we've had about where biotech should go next. Krish Ramadurai of @aixventureshq argues interpretability is the new scalability, and that the founders who build mechanistic, measurable platforms will define the next era of synthetic biology. He...
AI‑Native Platforms Treat Genome Like Code, Transform Biotech
Investor Liliana Nordbakk believes the genome behaves like code and AI-native biology platforms will transform biotech. Excited to have her speaking at #SynBioBeta2026. Visit the SynBioBeta website to read the full article. https://t.co/3WOSXsz1zy
Polygenic Scores Make Parental Genetic Choices More Intentional
Parents already make genetic decisions about the traits of their kids when they select a partner. Now those choices are becoming more conscious. @herasight is building polygenic scores that predict traits and diseases across diverse ancestries. Looking forward to hearing @JonathanAnomaly...
Rapamycin Fails to Slow Epigenetic Aging, Sinclair Concedes
David Sinclair says rapamycin had no measurable effect on slowing or reversing epigenetic aging in humans. This was a drug most of the longevity community supported. He was even a believer of it. It was found to extend lifespan in: • Inbred lab animals •...
Egg Bioreactors Replace CHO Cells in Biologics Production
We’ve optimized drug design with AI. Why are we still manufacturing with CHO like it’s the 1980s? Neion Bio is rethinking biologics production using chicken eggs as bioreactors. Excited to hear Sam Levin at #SynBioBeta2026. Visit the SynBioBeta website to read the full...
Future of Coding: AI Agents on Mobile, Instant Alerts
Sid Sijbrandij just said developers won't need a monitor, a desk or an IDE to ship production code very soon. He co-founded GitLab, a platform used by 30 million developers, and is now building Kilo, an AI coding tool. His prediction for...
Time-to-Market Is SynBio’s Biggest Scaling Hurdle
Great conversation with Jamie Bacher about the one challenge synbio must solve: time to market. Jamie argues that scaling biotech requires more than great strains—process dev, downstream, analytics, and new financing models all matter. Excited to have him at #SynBioBeta2026. Read the...
Cell‑Free DNA Production Ends Decades‑Old Cloning Bottleneck
Most of synthetic biology has been completely transformed in the last decade. DNA manufacturing? Still running on cloning workflows from the 1970s. That's the bottleneck Jodi Barrientos, CEO of @ribbonbiolabs, is tackling head-on — and she's on the @SynBioBeta Main Stage on...
Lowering Barriers Unlocks Biotech’s Biggest Potential
What if the biggest unlock in biotech is simply access? Douglas Crawford built MBC BioLabs to lower barriers and enable 500+ startups. Excited to have him at SynBioBeta 2026. Visit the @SynBioBeta website to read the full article. https://t.co/HEfhvmwZ8i
Sinclair Reverses Mouse Infertility, Challenges Menopause Limits
David Sinclair's lab just reversed infertility in mice that had been infertile for 6 months. They took 16-month-old mice, the equivalent of a woman well past menopause, and made them produce offspring again. The belief has always been that mammals run out...
Genetic-Level Solutions Needed; Dyno Tackles Untreatable Diseases
Eric Kelsic said: "To address the root cause of a genetic disease, you need to take action at the genetic level." But this isn’t possible today. If you have sickle cell, Huntington's or cystic fibrosis, there's no cure for you just yet. Here's...
Governments Back Alternative Proteins for Food Security and Jobs
6 years ago, zero governments were supporting alternative proteins. Now the goveernments at countries like Singapore, Israel, India, Brazil, Japan, South Korea, China, the UK, and the US are providing funding for it. There are a few driving forces behind it -...
AI Meets Scalable Single-Cell Data, Transforming Medicine
AI needs data. And biology is finally generating it at scale. I spoke with @10xGenomics CEO Serge Saxonov about the single-cell and spatial biology revolution — and why the convergence of AI + biological measurement could transform medicine. Read the full profile...
AI‑Designed Enzymes Signal SynBio’s Sugar‑Reduction Promise
Can synbio solve sugar reduction? The @ArzedaCo + @ManeGroup partnership is a strong signal. AI-designed enzymes Cell-free manufacturing at scale Real products in market Excited to host Alexandre Zanghellini (@biopraxis) at #SynBioBeta2026. Visit the SynBioBeta website to read the full article: https://t.co/1S29MUqfWh
Molecule‑Led Framework Prioritizes Coordination Over Technology
For years, we’ve talked about a trillion-dollar bioeconomy. The harder question has always been where to start. This new piece on the AB4S Molecule Manifesto from @LOrealGroupe, @Lallemande, @EITFood , @BASF, @Evonik, and @cradlebio offers one of the most compelling answers...
AI Simulates Patient Tumors, Transforming Oncology Research
@Ronalfa is speaking at @SynBioBeta in May and you probably already know who he is if you've been paying any attention to the AI x bio space. Ron spent years at @RecursionPharma as SVP of Research and acting CSO, helping build...
New AI Platform Uncovers Hidden Cancer Targets, Raises $10M
Most cancer drugs go after the same targets: EGFR. PD-L1. HER2. Not because they’re the best targets. Because they’re the only ones we’ve been able to see. RyboDyn Inc. is going after what’s been invisible. The San Diego team, led by Imad Ajjawi, PhD,...
Bridging Virtual Cells to Real Patients: The Next Frontier
Virtual biology burst onto the scene a few years ago. The idea was simple. Model the cell well enough, and you can predict biology before you test it. Large pharma has been thinking about this longer than most. PK/PD models, systems biology,...
Food Evolves Into Programmable Bioactive Layer for Health
There’s a shift happening in food that most people are still underestimating. Food is no longer just fuel. It is becoming a programmable layer on top of human biology. For decades, we’ve treated nutrition as static inputs. Calories in, calories out. Macros, vitamins,...
AI Aims to Slash Biotech’s $3B, 13‑year Drug Timeline
The biotech industry spends $3 billion and 13 years to bring one drug to market. If you're still searching for a treatment that works, it exists but the process discovering it is too slow to actually help you in time. How Marc...
We’re on the Brink of Self‑directed Human Evolution
When I was talking to Sergiy Velychko, a former postdoc from George Church's lab, about the future of human genome engineering, we discussed: “We're now at this point where we can engineer ourselves. We can do stem cell therapies. We can...
AI Simulates Cells to Accelerate Drug Discovery
AI didn’t just enter biology. It’s starting to rebuild it from first principles. @MichaBreakstone sold his last company for $575M. Then he went after a harder problem. What if you could model how cells signal, respond, and adapt… before you ever run an...
Better Meat, Not Less Meat, Will Reshape Food
The man quietly engineering the future of meat: Bruce Friedrich. This food systems scientist says we don't need people to eat less meat. We need better meat. Here are his 10 key insights on why alternative proteins will change everything: https://t.co/CDy9sXOh8J
Beyond AlphaFold: AI Generates Functional Proteins From Scratch
The AlphaFold moment was never the finish line. It was the starting gun. @saakohl helped build the system that cracked protein structure prediction… then left @GoogleDeepMind to go one step further. Design the molecules themselves. From scratch. In silico. Before a single experiment...
Aging Can Be Treated, Says Harvard Scientist Sinclair
The scientist trying to reverse aging in humans: David Sinclair. This Harvard researcher spent 30 years studying aging—and now says it's a treatable medical condition. He reveals how on the World Governments Summit: https://t.co/VRgBFtCiRW
Engineering Smarter, Healthier Babies Through Embryo Selection
The man engineering smarter, healthier babies before they're born: Jonathan Anomaly. This philosopher-turned-biotech founder says the future of your child's health starts at the embryo. Here are 9 things you need to know about embryo selection: https://t.co/XVQF5le4bE
First Human Age‑Reversal Trial Targets Whole‑Body Reset
The first human age-reversal trial is officially happening. But before the FDA cleared it, Harvard professor David Sinclair had to pull off a mice experiment most scientists thought was impossible: "These mice had their optic nerve regenerated. We were able to...
De Novo Enzymes Redefine Peptide Therapeutic Production
Peptide therapeutics are powerful. But making them has always been difficult. Traditional chemical synthesis can involve long routes, poor selectivity, and significant environmental impact, while biological production is often limited by the pathways evolution happened to provide. What if we could design...
Market‑First Synthetic Biology: Validate Demand Before Scaling Science
When Erum Khan asked me why 80% of biotech companies fail at execution, I replied: "The majority of synthetic biology founders have become enamored with the tool, the technology that they developed and then they went out there with that hammer...
Real‑time Biosurveillance Transforms Pandemics Into Preventable Events
Pandemics are still detected the same way they were decades ago. By the time we notice them, they are already spreading. What would it look like to treat pathogen surveillance like a real-time intelligence system? On Wednesday, May 6 at 8:35 AM, @PardisSabeti...
Aging Is Primarily Loss of Epigenetic Information
When Andrew Huberman asked about the root cause of aging, Dr. David Sinclair gave a surprisingly simple answer: "Aging is a loss of information in the same way you try to copy a cassette tape, or even if you send information...
Engineering Meat: Science Drives Next Agricultural Revolution
For 12,000 years, humanity has produced meat the same way: grow crops, feed animals, convert plants into protein. From a biomanufacturing perspective, it is one of the most complex and least optimized production systems on the planet. What happens when we start...
Your Partner Choice Shapes Your Child’s Health
Dr. Jonathan Anomaly said: "[Who you have children with] is going to be as or more effective than anything you do for your child's health.” If you want healthier, happier and brighter children, choose a healthier, happier and brighter partner. The 3...
Agentic AI Tackles Biology’s Exploding Complexity
Is biology finally becoming too complex for static models? For decades, biological modeling has relied on fixed equations, narrow simulations, and local approximations. That works until it doesn’t. Once you move into real systems, gene regulation, signaling cascades, protein networks, the...
De‑risking Synthetic Biology: From Lab to Market
What does it actually take to bring a biological product to market? For more than 20 years, Ingenza Ltd has helped teams avoid the most common failure points in synthetic biology. Freedom to operate issues. Low productivity. Fragile processes. Late CMC...
Rewire Your Brain at Any Age: 8 Key Insights
Andrew Huberman just hosted one of the world's leading neuroscientists. Dr. David Eagleman shared the science behind brain plasticity—diving deep into how to rewire it to become a better person at any age. Here are 8 takeaways that could reshape your life:...
AI‑Engineered AAV Capsid Makes Gene Delivery Programmable
One company is unlocking gene delivery to overcome the challenges that held back the promise of genetic medicine. If you want to learn more, they’ll be hosting an exclusive fireside chat at 9am Thursday, May 7th at SynBioBeta. Last year at...
AI Must Model Dynamic Biology, Not Static Proteins
There is one major barrier blocking AI from truly reshaping biology and no one is talking about it. Biology is not static. Most AI breakthroughs so far have treated proteins, cells, and systems as frozen objects. That abstraction worked to get...
